Literature DB >> 16765679

Family history of inflammatory bowel disease in patients with idiopathic ocular inflammation.

Phoebe Lin1, Howard H Tessler, Debra A Goldstein.   

Abstract

PURPOSE: To determine the prevalence of a family history (FMH) of inflammatory bowel disease (IBD) in patients with idiopathic ocular inflammation (OI).
DESIGN: Retrospective observational study.
METHODS: Medical records of idiopathic OI patients seen between January 1995 and June 2005 in the University of Illinois Uveitis Clinic were screened for a FMH of IBD. FMH included first, second, and third degree relatives.
RESULTS: 727 (32.8%) patients had idiopathic OI. 26 of 727 (3.6%) and 10 of 727 (1.4%) reported a FMH of ulcerative colitis (UC) and Crohn's disease, respectively. 16 (2.2%) patients with a FMH of indeterminate colitis were excluded from subsequent comparisons. The prevalence of a FMH of IBD among patients with idiopathic OI was 3- to 15-fold higher than the prevalence of UC and Crohn's in the general population (0.055% to 0.27%). Keratoiritis was more common and granulomatous disease less frequent in patients with a FMH of IBD (P = .014 and .019). Patients tested 26.3% with a FMH of IBD, and 66.7% of patients tested with IBD themselves, were HLA-B27 positive (odds ratio [OR] 5.6, 95% confidence interval [CI] 0.77 to 45.8), compared with 40.1% of patients with neither (OR 1.87, 95% CI 0.61 to 6.83).
CONCLUSIONS: A FMH of IBD may be an independent risk factor for the development of OI. In contrast to the subgroup of patients with a personal history of IBD, HLA-B27 may not be an appropriate marker in the subgroup of patients with merely a FMH of IBD, emphasizing the importance of investigating other immunologic factors that may predispose patients with IBD and their relatives to OI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16765679     DOI: 10.1016/j.ajo.2006.01.075

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.

Authors:  Sasha Taleban; Dalin Li; Stephan R Targan; Andrew Ippoliti; Steven R Brant; Judy H Cho; Richard H Duerr; John D Rioux; Mark S Silverberg; Eric A Vasiliauskas; Jerome I Rotter; Talin Haritunians; David Q Shih; Marla Dubinsky; Gil Y Melmed; Dermot P B McGovern
Journal:  J Crohns Colitis       Date:  2015-10-08       Impact factor: 9.071

2.  Etiologies of chronic anterior uveitis at a tertiary referral center over 35 years.

Authors:  Andrea D Birnbaum; Deborah M Little; Howard H Tessler; Debra A Goldstein
Journal:  Ocul Immunol Inflamm       Date:  2010-11-06       Impact factor: 3.070

3.  Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease.

Authors:  Javaneh Abbasian; Tammy M Martin; Sarju Patel; Howard H Tessler; Debra A Goldstein
Journal:  Am J Ophthalmol       Date:  2012-03-30       Impact factor: 5.258

4.  Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.

Authors:  Umesh C S Yadav; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

Review 5.  Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Authors:  Leandro Lopes Troncoso; Ana Luiza Biancardi; Haroldo Vieira de Moraes; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

6.  Orbital Inflammatory Complications of Crohn's Disease: A Rare Case Series.

Authors:  Tanya M Monaghan; Giorgio Albanese; Philip Kaye; James D Thomas; Lorraine C Abercrombie; Gordon W Moran
Journal:  Clin Med Insights Gastroenterol       Date:  2018-02-20

7.  Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era.

Authors:  Alix Cuny; Lucas Guillo; Cédric Baumann; Patrick Netter; Silvio Danese; Bénédicte Caron; Laurent Peyrin-Biroulet; Karine Angioi
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.